NO20062517L - 2-cyanopyrrolidinkarboksamidforbindelse - Google Patents
2-cyanopyrrolidinkarboksamidforbindelseInfo
- Publication number
- NO20062517L NO20062517L NO20062517A NO20062517A NO20062517L NO 20062517 L NO20062517 L NO 20062517L NO 20062517 A NO20062517 A NO 20062517A NO 20062517 A NO20062517 A NO 20062517A NO 20062517 L NO20062517 L NO 20062517L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- dpp
- independently
- cyanopyrrolidinkarboksamidforbindelse
- niddm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Abstract
Det beskrives en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav: I formel (I) har substituentene følgende betydninger: X1 og X2 er hver uavhengig lavere alkylen; X3 er =CH2, =CHF eller =CF2; R1 er en substituent, R2 og R3 er hver uavhengig H eller lavere alkyl; n er 0, 1, 2, 3 eller 4. Forbindelsene med formel (I) ovenfor rapporteres å ha inhiberende DPP-IV aktivitet og finner derfor anvendelse ved behandling av tilstander som medieres av DPP-IV, for eksempel NIDDM.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003906010A AU2003906010A0 (en) | 2003-10-31 | DPP-IV Inhibitor | |
AU2004900961A AU2004900961A0 (en) | 2004-02-25 | DPP-IV inhibitor | |
PCT/JP2004/016469 WO2005042533A2 (en) | 2003-10-31 | 2004-10-29 | 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-iv inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062517L true NO20062517L (no) | 2006-07-21 |
Family
ID=34553068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062517A NO20062517L (no) | 2003-10-31 | 2006-05-31 | 2-cyanopyrrolidinkarboksamidforbindelse |
Country Status (17)
Country | Link |
---|---|
US (1) | US7186731B2 (no) |
EP (1) | EP1737863B1 (no) |
JP (1) | JP4636021B2 (no) |
KR (1) | KR20060100390A (no) |
AR (1) | AR046313A1 (no) |
AT (1) | ATE419250T1 (no) |
BR (1) | BRPI0415587A (no) |
CA (1) | CA2543533A1 (no) |
CO (1) | CO5690603A2 (no) |
DE (1) | DE602004018837D1 (no) |
ES (1) | ES2320557T3 (no) |
IL (1) | IL175214A0 (no) |
MX (1) | MXPA06004797A (no) |
NO (1) | NO20062517L (no) |
RU (1) | RU2006118789A (no) |
TW (1) | TW200528440A (no) |
WO (1) | WO2005042533A2 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
AU2006245438A1 (en) * | 2005-02-18 | 2006-11-16 | Bellus Health (Innodia) Inc. | Analogs of 4-hydroxyisoleucine and uses thereof |
EP1874287A2 (en) * | 2005-03-22 | 2008-01-09 | Innodia Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
AP2007004234A0 (en) | 2005-04-22 | 2007-12-31 | Alantos Pharm Holding | Dipeptidyl peptidase-IV inhibitors |
AU2006278039B2 (en) * | 2005-08-11 | 2010-10-21 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a DPP-lV inhibitor |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20100048545A1 (en) * | 2006-03-22 | 2010-02-25 | Innodia Inc. | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
GB0713602D0 (en) * | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
US8338450B2 (en) * | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
US8999975B2 (en) * | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
MD4754C1 (ro) | 2012-12-21 | 2021-12-31 | Gilead Sciences, Inc. | Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică |
DK2970283T3 (da) | 2013-03-14 | 2021-01-25 | Boehringer Ingelheim Int | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c |
JP6441831B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンcの置換2−アザ−ビシクロ[2.2.2]オクタン−3−カルボン酸(ベンジル−シアノ−メチル)−アミド阻害剤 |
NO2865735T3 (no) | 2013-07-12 | 2018-07-21 | ||
AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (no) | 2014-06-20 | 2018-06-23 | ||
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
EP3174879B1 (en) | 2014-08-01 | 2018-07-18 | Boehringer Ingelheim International GmbH | Substituted oxetanes and their use as inhibitors of cathepsin c |
NZ728684A (en) | 2014-09-12 | 2022-09-30 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
WO2018187350A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
IT201700059292A1 (it) * | 2017-05-31 | 2018-12-01 | Univ Pisa | Derivati 1,3-diaza-4-ossa-[3.3.1]-biciclici, loro preparazione e uso come medicinale, in particolare per il trattamento del diabete |
CA3108449A1 (en) | 2018-08-08 | 2020-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active bridged piperidine derivative |
EP3845533A4 (en) | 2018-08-27 | 2022-04-27 | Sumitomo Dainippon Pharma Co., Ltd. | OPTICALLY ACTIVE AZABICYCLIC DERIVATIVES |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003057144A2 (en) * | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
-
2004
- 2004-10-28 TW TW093132734A patent/TW200528440A/zh unknown
- 2004-10-29 US US10/975,524 patent/US7186731B2/en not_active Expired - Fee Related
- 2004-10-29 WO PCT/JP2004/016469 patent/WO2005042533A2/en active Application Filing
- 2004-10-29 CA CA002543533A patent/CA2543533A1/en not_active Abandoned
- 2004-10-29 KR KR1020067007974A patent/KR20060100390A/ko not_active Application Discontinuation
- 2004-10-29 ES ES04793389T patent/ES2320557T3/es active Active
- 2004-10-29 RU RU2006118789/04A patent/RU2006118789A/ru not_active Application Discontinuation
- 2004-10-29 EP EP04793389A patent/EP1737863B1/en not_active Not-in-force
- 2004-10-29 BR BRPI0415587-4A patent/BRPI0415587A/pt not_active IP Right Cessation
- 2004-10-29 JP JP2006518489A patent/JP4636021B2/ja not_active Expired - Fee Related
- 2004-10-29 MX MXPA06004797A patent/MXPA06004797A/es not_active Application Discontinuation
- 2004-10-29 AR ARP040104001A patent/AR046313A1/es not_active Application Discontinuation
- 2004-10-29 AT AT04793389T patent/ATE419250T1/de not_active IP Right Cessation
- 2004-10-29 DE DE602004018837T patent/DE602004018837D1/de not_active Expired - Fee Related
-
2006
- 2006-04-26 CO CO06039525A patent/CO5690603A2/es not_active Application Discontinuation
- 2006-04-26 IL IL175214A patent/IL175214A0/en unknown
- 2006-05-31 NO NO20062517A patent/NO20062517L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005042533A2 (en) | 2005-05-12 |
US20050137224A1 (en) | 2005-06-23 |
EP1737863B1 (en) | 2008-12-31 |
US7186731B2 (en) | 2007-03-06 |
EP1737863A2 (en) | 2007-01-03 |
WO2005042533A3 (en) | 2005-09-01 |
JP2007510619A (ja) | 2007-04-26 |
IL175214A0 (en) | 2006-09-05 |
ATE419250T1 (de) | 2009-01-15 |
BRPI0415587A (pt) | 2007-01-02 |
DE602004018837D1 (de) | 2009-02-12 |
RU2006118789A (ru) | 2007-12-10 |
KR20060100390A (ko) | 2006-09-20 |
TW200528440A (en) | 2005-09-01 |
MXPA06004797A (es) | 2006-07-03 |
AR046313A1 (es) | 2005-11-30 |
JP4636021B2 (ja) | 2011-02-23 |
ES2320557T3 (es) | 2009-05-25 |
CA2543533A1 (en) | 2005-05-12 |
CO5690603A2 (es) | 2006-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062517L (no) | 2-cyanopyrrolidinkarboksamidforbindelse | |
NO20080030L (no) | Nye mandelsyre-derivater og anvendelse derav som trombininhibitorer | |
YU77101A (sh) | Inhibitori renina | |
NO20051600L (no) | 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer | |
NO20062950L (no) | 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet | |
EP1679069A4 (en) | NEW PIPERIDINE DERIVATIVE | |
NO20063330L (no) | Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer | |
NO20004485L (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
NO20022124L (no) | Imidazopyridinderivater som fosfodiesterase VII-inhibitorer | |
NO20050612L (no) | Pyrrolidinderivater som oksytocinantagonister | |
MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
ATE277011T1 (de) | Flouride von 4-substituierten piperidin-derivaten | |
EP1500648A4 (en) | NEW PIPERIDINE DERIVATIVES | |
NO20051925L (no) | Fungicide blandinger. | |
DK1157998T3 (da) | Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer | |
SE0100326D0 (sv) | New compounds | |
NO20082226L (no) | 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav | |
ATE109467T1 (de) | Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropy idinderivaten als freie radikalfänger. | |
ATE308540T1 (de) | Antithrombosemittel | |
YU52498A (sh) | UPOTREBA 2-ARILBENZO (b) TIOFENA ZA DOBIJANJE LEKA | |
DK1899331T3 (da) | Homomorpholinoxazolidnoner som antibakterielle midler | |
HRP20020440B1 (en) | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | |
NO20053726L (no) | Forbindelser med prolyloligopeptidase-hemmende aktivitet | |
SE0300705D0 (sv) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |